home / stock / rttr / rttr news

RTTR News and Press, Ritter Pharmaceuticals From 09/13/19

Stock Information
Company Name: Ritter Pharmaceuticals
Stock Symbol: RTTR
Market: NASDAQ
Menu
RTTR RTTR Quote RTTR Short RTTR News RTTR Articles RTTR Message Board
Get RTTR Alerts

News, Short Squeeze, Breakout and More Instantly...
RTTR - Leerink likes Acadia Pharma in premarket analyst action

Denali Therapeutics (NASDAQ: DNLI ) initiated with Buy rating and $35 (84% upside) price target at Nomura Instinet. More news on: Denali Therapeutics Inc., Intuitive Surgical, Inc., ACADIA Pharmaceuticals Inc., Healthcare stocks news, Stocks on the move, , Read more ...

RTTR - Ritter Pharma's RP-G28 flunks late-stage study

Thinly traded nano cap Ritter Pharmaceuticals (NASDAQ: RTTR ) is poised for a significant down move after announcing that a Phase 3 clinical trial evaluating lead candidate RP-G28 for the treatment of lactose intolerance (LI) failed to achieve the primary endpoint. More news on: Ritter...

RTTR - Ritter Pharmaceuticals Reports Top-Line Results from its Liberatus Phase 3 Trial of RP-G28 for Lactose Intolerance

LOS ANGELES, Sept. 12, 2019 (GLOBE NEWSWIRE) -- Ritter Pharmaceuticals, Inc. (Nasdaq: RTTR) (“Ritter Pharmaceuticals” or the “Company”), a developer of innovative therapeutic products that modulate the gut microbiome to treat gastrointestinal diseases, annou...

RTTR - Ritter Pharmaceuticals EPS beats by $0.18

Ritter Pharmaceuticals (NASDAQ: RTTR ): Q2 GAAP EPS of -$0.31 beats by $0.18 . More news on: Ritter Pharmaceuticals, Inc., Earnings news and commentary, Healthcare stocks news, , Read more ...

RTTR - Ritter Pharmaceuticals Reports Financial Results for the Three and Six Months Ended June 30, 2019 and Provides a Corporate Update

LOS ANGELES, Aug. 14, 2019 (GLOBE NEWSWIRE) -- Ritter Pharmaceuticals, Inc. (Nasdaq: RTTR) (“Ritter Pharmaceuticals” or the “Company”), a developer of innovative therapeutic products that modulate the gut microbiome to treat gastrointestinal diseases with an init...

RTTR - Ritter Pharmaceuticals Appoints Esteemed Gastroenterologist Anthony J. Lembo, M.D. to its Medical Advisory Board

LOS ANGELES, Aug. 13, 2019 (GLOBE NEWSWIRE) -- Ritter Pharmaceuticals, Inc. (Nasdaq: RTTR) (“Ritter Pharmaceuticals” or the “Company”), a developer of innovative therapeutic products that modulate the gut microbiome to treat gastrointestinal (GI) diseases, today ...

RTTR - Ritter Pharmaceuticals Provides Highlights from Lactose Intolerance Market Research Call

Market research indicates an unmet need for better lactose intolerance treatments and interest from both patients and physicians in the RP-G28 drug profile LOS ANGELES, Aug. 08, 2019 (GLOBE NEWSWIRE) -- Ritter Pharmaceuticals, Inc. (Nasdaq: RTTR) (“Ritter Pharmaceuticals”...
RTTR - Ritter Pharmaceuticals Hosts Conference Call on August 7, 2019 to Highlight Recent Lactose Intolerance Market Research Findings

Daniel P. Lundberg, Consultant to Ritter Pharmaceuticals and former Senior VP of Marketing at Salix Pharmaceuticals to address market opportunity for Phase 3, lactose intolerance drug candidate RP-G28 LOS ANGELES, July 31, 2019 (GLOBE NEWSWIRE) -- Ritter Pharmaceuticals, Inc. (Nasdaq: R...

RTTR - RDHL, SFIX among premarket gainers

Medigus (NASDAQ: MDGS ) +49%  on large order for visualization device. More news on: Medigus Ltd., VivoPower International PLC, HOOKIPA Pharma Inc., Stocks on the move, Read more ...

RTTR - Ritter Pharmaceuticals Regains Compliance with Nasdaq's Minimum Bid Price Requirement

Ritter Shares Will Continue to Trade on the Nasdaq Capital Market LOS ANGELES, July 11, 2019 (GLOBE NEWSWIRE) -- Ritter Pharmaceuticals, Inc. (Nasdaq: RTTR) (“Ritter Pharmaceuticals” or the “Company”), a developer of innovative therapeutic products that mo...
Previous 10 Next 10